|
Characteristics
|
No. of patients (N = 156) (%)
|
|---|
|
Age (years, mean ± SD)
|
52.8 ± 12.0
|
|
Histologic grade
|
|
I
|
13 (8.3)
|
|
II
|
107 (68.6)
|
|
III
|
36 (23.1)
|
|
Tumor stage
|
|
T1
|
77 (49.4)
|
|
T2
|
79 (50.6)
|
|
Nodal stage
|
|
Negative
|
96 (61.5)
|
|
Positive
|
60 (38.5)
|
|
TNM stage
|
|
I
|
50 (32.1)
|
|
II
|
106 (67.9)
|
|
E-cad
|
|
Negative/low
|
27 (17.3)
|
|
Positive
|
129 (82.7)
|
|
ER
|
|
Negative
|
52 (33.3)
|
|
Positive
|
104 (66.7)
|
|
PR
|
|
Negative
|
82 (52.6)
|
|
Positive
|
74 (47.4)
|
|
HER2
|
|
Negative
|
129 (82.7)
|
|
Positive
|
27 (17.3)
|
|
Ki67
|
|
Negative
|
40 (25.6)
|
|
Positive
|
116 (74.4)
|
|
Molecular subtypes
|
|
Luminal A
|
30 (19.2)
|
|
Luminal B
|
74 (47.4)
|
|
HER2-enriched
|
14 (9.0)
|
|
TNBC
|
38 (24.4)
|
-
IHC immunohistochemistry, IDC invasive ductal carcinoma of the breast, TNBC triple-negative breast cancer
